Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.

Latest results

Portfolio metrics

Approved products
Development-stage therapies
Blockbuster products (>$1bn in annual sales)
Portfolio duration

Financial metrics

Portfolio Receipts
Adjusted EBITDA
Average annual capital deployed (2018-2023)
Announced value of transactions (2023)

Corporate presentation

SEC filings

Filing Date Form View
All Filings

Latest releases

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

NEW YORK, NY and SOUTH SAN FRANCISCO, CA, May 22, 2024 – Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.

Stay up to date

Subscribe to Royalty Pharma news and alerts